Inhibiting sphingosine-1-phosphate lyase as a possible therapy in Huntington’s disease
Objective: To advance our understanding of the process by which the mutant huntingtin (mHTT) protein contributes to neurodegeneration and translate that knowledge to potentially effective disease…Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): Results of a Cohort Comparison of Open-HART and Historical Placebo Subjects
Objective: To measure functional decline by TFC change in HD patients treated with open-label pridopidine at 45 mg BID (Open-HART) for 36 months (mos), and…Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial
Objective: To implement and validate quantification of motor dysfunction in a Huntington disease (HD) clinical trial using machine learning algorithmic analysis derived from biometric monitoring…A Descriptive Analysis of a Real-World Population With Huntington Disease-Associated Chorea (HDAC) Treated With Tetrabenazine: Findings From an Electronic Medical Records (EMR) Database
Objective: To examine clinical and treatment information about HDAC in patients (pts) prescribed tetrabenazine (TBZ). Background: Huntington disease is a hereditary movement disorder, with chorea…Dynamic prediction of motor diagnosis in Huntington’s disease using a joint modeling approach
Objective: Compare various clinical and biomarker trajectories for tracking Huntington's disease (HD) progression and predicting motor conversion. Background: Huntington’s disease (HD) is a fatal neurodegenerative disease…Demographic and Clinical Characteristics and Tetrabenazine (TBZ) Persistence in Patients With Huntington Disease (HD)-Associated Chorea
Objective: To characterize demographic and clinical characteristics of HD patients with chorea based on TBZ use status, and to examine treatment persistence with TBZ in…Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
Objective: To assess efficacy, safety, and tolerability of multiple doses of pridopidine in HD patients (pts) with signs of motor dysfunction. Background: Prior trials suggested…Clinical and genetic characterization of Huntington’s disease in relation to the age and type of onset.
Objective: To describe the clinical features and CAG repeats in a large population of Mexican patients with Huntington's disease and its relation to the age…Prescription pattern of treatment in Mexican patients with Huntington’s Disease.
Objective: To describe the prescription pattern for the treatment of HD in a sample of Mexican patients from a tertiary referral center. Background: Huntington’s disease…Prevalence of substance abuse in Huntington´s disease patients and its relationship with neuropsychiatric symptoms
Objective: To describe the prevalence of substance abuse and its relationship with neuropsychiatric features in Huntington’s disease (HD). Background: Substance abuse is not well established…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.